Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

Inclusion criteria: * Age \>=18 years * Histologically confirmed RCC with a clear-cell component * Locally advanced or metastatic RCC * At least one measurable lesion per RECIST 1.1 criteria, as determined by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) * No systemic therapy for advanced or metastatic RCC prior to enrollment * Karnofsky Performance Status (KPS) ≥70 * Adequate baseline organ function * A female was eligible to enter and participate in this study if she was of: non-childbearing potential, or negative serum pregnancy test with agreement to use adequate contraception during the study * A male with female partner of childbearing potential must have vasectomy/agree to use effective contraception from 2 weeks prior to administration of the 1st dose of study treatment for a period of time after the last dose of study treatment * Able to swallow and retain orally administered medication and must not have clinically significant GI abnormalities that may alter absorption Additional inclusion criteria for starting everolimus: * Disease progression must be within 6 months after stopping pazopanib * At least one measurable lesion at the start of everolimus pe r RECIST 1.1 criteria, as determined by CT or MRI * In case of central nervous system (CNS) progression or metastasis during pazopanib treatment: asymptomatic or neurologically stable, no requirement of steroids to control CNS symptoms, and no requirement of enzyme-inducing anticonvulsants within 4 weeks prior to the start of everolimus Exclusion Criteria: * Lactating female * History of another malignancy (exception: patients disease-free for ≥3 years and patients with completely resected non-melanoma skin cancer or successfully treated in situ carcinoma) * Symptomatic CNS metastases at baseline * Clinically significant gastrointestinal abnormalities * Moderate to severe hepatic impairment (Child Pugh Class C) * Receiving chronic treatment with corticosteroids/other immunosuppressive agents * Active bleeding, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin) * Corrected QT interval (QTc) \>480 msec using Bazett's formula * Presence of any severe or uncontrolled medical conditions/infection * Poorly controlled hypertension (defined as systolic blood pressure of \>=140mmHg or diastolic blood pressure of \>=90mmHg) * History of cardiovascular disorders within the last 12 months (e.g. myocardial infraction or unstable angina), history of cerebrovascular events or pulmonary embolism within the last 6 months * Active bleeding or bleeding susceptibility * Known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that increased the risk of pulmonary hemorrhage Additional criteria for exclusion from the second-line everolimus treatment period: \- The subject felt by the investigator to be unsuitable (on the basis of health, compliance, or for any other reason) for inclusion in the study.